Ayala Pharmaceuticals (ADXS) Competitors $0.03 0.00 (0.00%) As of 12:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends ADXS vs. BNOX, PRTG, UPXI, TNFA, OGEN, BPTH, CPHI, FRTX, CELZ, and ENVBShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Bionomics (BNOX), Portage Biotech (PRTG), Upexi (UPXI), TNF Pharmaceuticals (TNFA), Oragenics (OGEN), Bio-Path (BPTH), China Pharma (CPHI), Fresh Tracks Therapeutics (FRTX), Creative Medical Technology (CELZ), and Enveric Biosciences (ENVB). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Bionomics Portage Biotech Upexi TNF Pharmaceuticals Oragenics Bio-Path China Pharma Fresh Tracks Therapeutics Creative Medical Technology Enveric Biosciences Ayala Pharmaceuticals (NASDAQ:ADXS) and Bionomics (NASDAQ:BNOX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk. Does the media prefer ADXS or BNOX? In the previous week, Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Bionomics'average media sentiment score. Company Overall Sentiment Ayala Pharmaceuticals Neutral Bionomics Neutral Is ADXS or BNOX more profitable? Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A Bionomics N/A N/A N/A Which has more volatility & risk, ADXS or BNOX? Ayala Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Bionomics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Do insiders & institutionals believe in ADXS or BNOX? 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.9% of Bionomics shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Bionomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, ADXS or BNOX? Bionomics has lower revenue, but higher earnings than Ayala Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$3.24M0.36-$48.07M-$7.980.00Bionomics$10K446.82-$15.49MN/AN/A Does the MarketBeat Community prefer ADXS or BNOX? Bionomics received 20 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 76.92% of users gave Bionomics an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAyala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes70100.00% BionomicsOutperform Votes2076.92% Underperform Votes623.08% Do analysts rate ADXS or BNOX? Bionomics has a consensus price target of $8.00, suggesting a potential upside of 3,060.81%. Given Bionomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionomics is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bionomics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBionomics beats Ayala Pharmaceuticals on 9 of the 11 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio0.0010.0188.8317.53Price / Sales0.36335.611,282.2680.28Price / CashN/A22.6336.6032.90Price / Book-0.015.084.964.69Net Income-$48.07M$154.90M$117.89M$224.57M7 Day PerformanceN/A2.59%2.75%3.33%1 Month PerformanceN/A1.52%3.63%5.33%1 Year PerformanceN/A5.49%27.27%22.97% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03flatN/A-95.6%$1.15M$3.24M0.0020Analyst ForecastGap UpBNOXBionomics1.6868 of 5 stars$0.25+4.2%$8.00+3,060.8%-75.9%$4.47M$10,000.000.00N/APositive NewsGap UpHigh Trading VolumePRTGPortage Biotech0.084 of 5 stars$4.25-2.7%N/A-80.7%$4.46MN/A-0.106Gap DownUPXIUpexi2.4408 of 5 stars$3.83-0.5%$25.00+552.7%-85.5%$3.99M$22.08M0.00130Positive NewsGap DownTNFATNF PharmaceuticalsN/A$1.43+13.0%N/AN/A$3.94MN/A0.006Positive NewsHigh Trading VolumeOGENOragenicsN/A$0.32-6.7%N/AN/A$3.91M$40,000.00-0.055News CoverageBPTHBio-Path1.4865 of 5 stars$0.91-4.6%$20.00+2,107.5%-89.9%$3.90MN/A0.0010Analyst ForecastNews CoverageCPHIChina PharmaN/A$0.20-7.9%N/A-54.8%$3.90M$5.54M0.00231News CoverageGap DownFRTXFresh Tracks TherapeuticsN/A$0.65-8.6%N/A-32.7%$3.88M$10.06M-0.4620Gap DownCELZCreative Medical TechnologyN/A$2.22+2.3%N/A-46.3%$3.88M$11,000.00-0.585Positive NewsGap UpENVBEnveric Biosciences3.1017 of 5 stars$0.38-5.5%$10.00+2,531.6%-67.5%$3.87MN/A-0.1520Gap Down Related Companies and Tools Related Companies Bionomics Alternatives Portage Biotech Alternatives Upexi Alternatives TNF Pharmaceuticals Alternatives Oragenics Alternatives Bio-Path Alternatives China Pharma Alternatives Fresh Tracks Therapeutics Alternatives Creative Medical Technology Alternatives Enveric Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADXS) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADXS Stock Alerts